MedTrace Logo

Topical Tranexamic Acid (TXA) in Joint Arthroplasty

NCT01937559 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 188

Last updated 2020-05-05

Study results available
· View outcomes & findings →

Summary

The objective of this study is to evaluate the efficacy of topical tranexamic acid (TXA) in decreasing blood loss following both shoulder arthroplasty and primary total hip arthroplasty. TXA functions to decrease blood loss by affecting the blood clotting system within the body. The investigators hypothesize that topical application of TXA prior to closure reduces postoperative bleeding as measured by absolute changes in postoperative hemoglobin levels and surgical drain output. In addition, use of topically applied tranexamic acid may reduce the need for transfusions, the rates of hematomas, infections, and length of hospital stay.

Conditions

Interventions

BIOLOGICAL

Tranexamic acid (TXA)

1.5g of TXA in 100ml normal saline solution

DRUG

Normal saline

Sponsors & Collaborators

  • The Hawkins Foundation

    lead OTHER

Principal Investigators

  • Brian Burnikel, MD · Steadman Hawkins Clinic of the Carolinas - Greenville Health System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2018-06-30
Completion
2018-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01937559 on ClinicalTrials.gov